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The synthesis of six novel N-heterocyclic carbene silver(I) acetate complexes, three symmetrical and
three non-symmetrical, were achieved using 4,5-diphenylimidazole to produce intermediate imida-
zolium salts and then obtain the corresponding silver(I) complexes through complexation with silver
acetate via the Youngs’ method. In vitro biological testing, using the Kirby–Bauer disk diffusion method,
was conducted against Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli, with a
NHC–silver(I) acetate compound, SBC3, and Tetracycline as standards. Silver(I) acetate complex 7
resulted in a 4 mm clearance against MRSA, showing the highest antibiotic activity of the novel deriva-
tives. Crystallographic data revealed similar bond lengths and angles to previously reported NHC–sil-
ver(I) acetate complexes, with complex 8 showing interesting g2-coordination between the silver
atom and acetate oxygens. 109Ag NMR studies were conducted, highlighting the effects of the substituents
of the imidazole ring on the silver atom shown by the corresponding shifts in the 109Ag NMR spectra. The
incorporation of isopropyl groups to several of the novel complexes resulted in larger upfield 109Ag NMR
shift values compared to all other substituents.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Antimicrobial resistance has become a global phenomenon [1,2]
and with cornerstone antibiotic classes becoming less effective
[3,4] there is increasing need for new resistance breaking antibiotic
compounds. In order to overcome developing resistance, future
generation of antibiotics will have to employ multiple mechanisms
of action to decrease the chance of such resistance developing, as
well as break current resistant strains [5].
For this purpose, silver is a reliable choice for incorporation into
a new antibiotic class. With recent research highlighting that its
combination with frontline antibiotics can increase their potency
[6]. The decades of clinical use as burn wound creams have
resulted in infrequent reports of sustained silver resistance,
which could be contributed to silver’s multiple mechanisms of
bactericidal action, including transport protein disruption and
redox enzyme inhibition [7,8].
To utilise and enhance silver’s proven antibiotic ability, N-hete-
rocyclic carbenes (NHCs) can be incorporated as supplementarybiomolecules. Since the isolation of a stable, singlet carbene by
Arduengo [9], N-heterocyclic carbene research has dramatically
increased in areas of catalysis and medicinal chemistry [12]. The
work of Youngs in the mid-2000’s then highlighted the usage of
NHC–silver(I) acetate compounds derived from xanthine against
bacterial pathogens in the lungs [10]. Since this work, the knowl-
edge base of NHC–Ag(I) complexes has been greatly expanded
and reviewed extensively [11,12,22].
In order to increase antibacterial ability, the transport of NHC–
silver(I) complexes into bacterial cells is an important factor. The
large derivability of imidazole-based NHCs [15,24–28] allows for
the incorporation of substituent groups that can bestow
improved bioavailability and electronically influence the slow
release of silver cations in the intracellular environment through
the strong r-bonding of the NHC [13].
Lipophilic character of the stabilising NHC ligand has been
shown to be a key characteristic in NHC–Au(I) anticancer com-
pounds [14,21]. Previous research by our group has led to the
hypothesis that lipophilic substituents are a large factor by which
the antibiotic compound SBC3, a silver(I) complex containing four
lipophilic phenyl rings (Fig. 1) [15], is so effective against gram-
positive bacteria such as Staphylococcus aureus and its widespread
Fig. 1. 1,3-Dibenzyl-4,5-diphenylimidazol-2-ylidene silver(I) acetate (SBC3) [15].
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[16,17].
In an attempt to increase the antibacterial activity of this NHC–
silver(I) acetate compound class, the molecular weight was
decreased in six new NHC–silver(I) acetate compound. The incor-
poration of lower molecular weight alkyl chains will improve the
drug-like character of the new complexes [18], whilst retaining
some lipophilic character that is hypothesized to make the
previous SBC3 complex so effective [15]. To assess this hypothesis,
all complexes were tested for antibacterial activity using the
Kirby–Bauer disk diffusion method against MRSA and Escherichia
coli [19].
In addition to the synthesis and testing of these novel NHC–sil-
ver(I) complexes, 109Ag NMR studies were conducted. Silver has
two isotopes, 107Ag and 109Ag, each with a spin of ½ and although
107Ag has a slightly higher natural abundance compared to 109Ag
(51.8% versus 48.2%, respectively), the NMR studies are usually
done using the 109Ag isotope as it has a higher gyromagnetic ratio.
Even if the largest problems remain the low sensitivity and long
relaxation times of the silver isotopes [23], the use of 109Ag NMR
studies could determine interesting analytical information for this
class of NHC–silver(I) compounds.
Crystal structures were obtained for all complexes 3–8 and
structural information will be reviewed for any influence on the
characteristic bonds observed in these types of NHC–silver(I) com-
plexes. The g2-coordination between the silver(I) moiety and acet-
ate oxygens are two and the possible argentophilic interactions are
two notable phenomena that have previously been reported and
were surveyed for in this work [15,24–28].
2. Experimental
2.1. General considerations
Unless otherwise stated in the synthesis procedures, all chemi-
cals and solvents were used as supplied from commercial sources
without further purification or drying. The melting points of the
corresponding compounds were measured using a StuartTM melting
point apparatus SMP10, AC input 230 V and were uncorrected. 1H
and 13C NMR spectra were obtained at room temperature on a Var-
ian VnmrS 400 MHz spectrometer and 109Ag NMR spectra were
obtained on an Agilent DD2 500 MHz spectrometer. All NMR data
was collected using CDCl3 as deuterated solvent which contains
0.03% (v/v) TMS. 1H NMR chemical shifts were referenced to
TMS. All other spectra were referenced using absolute referencing
from a referenced proton spectrum. For obtaining 109Ag NMR spec-
tra, a 1H NMR measurement was simultaneously obtained using
CDCl3 as the deuterated solvent and Tetramethylsilane (TMS) as
internal references. Total elemental analysis was undertaken using
an Exeter Analytical CE-440 elemental analyser. Infrared spectra
were obtained using a Bruker ALPHA Platinum ATR spectrometer.2.2. Synthesis
All synthesis procedures carried out at over 100 C were under-
taken in sealed, pressurised containers. All silver complex synthe-
sises were carried out under nitrogen and in lightproof flasks.
Several silver complexes were purified using Davisil 40–63
micron silica using pencil columns fashioned from Pasteur pip-
ettes, with dichloromethane used as the eluent.2.3. Synthesis of 1-methyl-3-benzyl-4,5-diphenylimidazolium bromide
(1)
1-Methyl-4,5-diphenyl Imidazole (0.234 g, 1.00 mmol) and
benzyl bromide (0.12 ml, 1.00 mmol) were placed in 30 ml ace-
tonitrile and stirred under reflux at 85 C for 24 h. The solution
was filtered and washed with 10 ml acetonitrile. The filtrate was
concentrated down to 3 ml and then 50 ml diethyl ether was
added. The product was then filtered and dried in vacuo for 2 h
to produce an off-white solid (0.367 g, 90% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 11.00 (1H, NCHN, s), 7.48–
7.36 (6H, CHArom, m), 7.28–7.27 (3H, CHArom, m), 7.22 (2H, CHArom,
dd, 8, 1.5 Hz), 7.16–7.12 (4H, CHArom, m), 5.48 (2H, CH2, s), 3.96
(3H, CH3, s).
13C NMR (100.553 MHz, CDCl3, ppm): 137.8, 133.2, 132.5, 131.7,
130.8, 130.5, 130.4, 130.2, 129.3, 129.2, 129.1, 128.6, 124.8, 124.4
(CArom), 51.2 (CH2), 35.1 (CH3).
Elemental Analysis calculated for C23H21N2Br: Calculated: C,
68.15; H, 5.22; N, 6.91; Found: C, 67.80; H, 5.15; N, 6.63.
IR (KBr, cm1): 3117 (w), 2998 (w,v), 1560 (w), 1441 (w), 766
(m), 736 (m), 700 (s), 517 (w), 463 (w).
Melting point: 239–240 C.2.4. Synthesis of 1-isopropyl-3-benzyl-4,5-diphenylimidazolium
bromide (2)
1-Isopropyl-4,5-diphenyl Imidazole (0.262 g, 1.00 mmol) and
benzyl bromide (0.14 ml, 1.2 mmol) were placed in 20 ml acetoni-
trile and stirred for 3 d. The solution was filtered and washed with
10 ml acetonitrile. The filtrate was concentrated down to 3 ml and
80 ml diethyl ether was added. The resulting precipitate was
allowed to settle for 10 min before being filtered in vacuo for 2 h
to retrieve an off-white solid. (0.230 g, 54% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 11.25 (1H, NCHN, s), 7.46–
7.31 (6H, CHArom, m), 7.25–7.20 (5H, CHArom, m), 7.15–7.10 (4H,
CHArom, m), 5.67 (2H, CH2, s), 4.45 (1H, CHIsopropyl, hept, 7 Hz),
1.70 (6H, CH3Isopropyl, d, 1.5 Hz).
13C NMR (100.553 MHz, CDCl3, ppm): 136.0, 133.8, 131.8, 131.5,
130.8, 130.5, 130.4, 130.4, 129.2, 129.1, 128.9, 128.8, 125.0, 124.4
(CArom), 51.6 (CH Isopropyl), 51.1 (CH2 Benzyl), 23.5 (CH3 Isopropyl).
Elemental Analysis calculated for C25H25N2Br: Calculated: C,
69.28; H, 5.81; N, 6.46; Found: C, 68.35; H, 5.71; N, 6.43.
IR (KBr, cm1): 3095 (w), 2973 (w,v), 1547 (m), 1452 (w), 1183
(w), 769 (m), 737 (s), 706 (m,v), 521 (w), 459 (w).
Melting point: 217–218 C.2.5. General procedure for silver(I) complexes 3–8
1.00 mmol of precursor imidazolium salt was stirred with 2.00
mmol of silver acetate (0.333 g) in 50 ml of dry dichloromethane
for 3 d. The reaction mixture was filtered, concentrated to 3 ml
and 50 ml diethyl ether was added. The resulting solution was
placed in a freezer at 4 C for 12 h and the resulting solid filtered
and dried in vacuo for 4 h to yield complexes 3–8.
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(I) acetate (3)
Silver(I) complex 3 was prepared as an off white solid. (0.227 g,
mmol, 55% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.36–7.34 (6H, CHArom, dd,
5, 2 Hz), 7.19–7.16 (4H, CHArom, m), 3.73 (6H, CH3Methyl, s), 2.11
(3H, CH3 AgOAc, s).
13C NMR (100.553 MHz, CDCl3, ppm): 179.2 (NCN), 132.2, 130.3,
129.1, 128.8, 127.9 (CArom), 37.5 (CMethyl), 22.9 (CAgOAc).
109Ag NMR (23.278 MHz, CDCl3, ppm): 476.
Elemental Analysis calculated for C19H19N2AgO2: Calculated: C,
54.96; H, 4.61; N, 6.75; Found: C, 54.00; H, 4.46; N, 6.55.
IR (KBr, cm1): 3535 (w,v), 3053 (w,v), 2951 (w,v), 1567 (s),
1374 (s), 1328 (s), 1012 (w), 765 (s), 698(s), 664 (s), 625 (s), 515
(m,v).
Melting point: 198–201 C.
2.5.2. Synthesis of 1,3-diethyl-4,5-diphenylimidazol-2-ylidene silver(I)
acetate (4)
Silver(I) complex 4, was prepared as a light brown solid (0.156
g, 36% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.35–7.33 (6H, CHArom, dd,
5, 2 Hz), 7.20–7.18 (4H, CHArom, m), 4.13 (4H, CH2 Ethyl, q, 7 Hz),
2.12 (3H, CH3 AgOAc, s), 1.23 (6H, CH3 Ethyl, t, 7 Hz).
13C NMR (100.553 MHz, CDCl3, ppm): 179.2 (NCN), 131.6, 130.4,
129.1, 128.7, 128.2 (CArom), 44.9 (CH2 Ethyl), 22.9 (CH3 AgOAc), 17.3
(CH3 Ethyl).
109Ag NMR (23.278 MHz, CDCl3, ppm): 480.
Elemental Analysis calculated for C21H23N2AgO2: Calculated: C,
56.89; H, 5.22; N, 6.31; Found: C, 57.35; H, 5.31; N, 6.12.
IR (KBr, cm1): 3052 (w,v), 2925 (w,v), 1578 (m,v), 1400 (m),
1340 (m,v), 767 (w,v), 699 (s), 666(m).
Melting point: 212–215 C.
2.5.3. Synthesis of 1,3-diisopropyl-4,5-diphenylimidazol-2-ylidene
silver(I) acetate (5)
Silver(I) complex 5, was prepared as a light brown solid. (0.120
g, 26% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.34–7.31 (CHArom, 6H, m),
7.17–7.14 (CHArom, 4H, m), 4.40 (CHIsopropyl, 2H, 7 Hz, hept), 2.13
(CH3AgOAc, 3H, s), 1.66 (CH3 Isopropyl, 12H, 7 Hz, d).
13C NMR (100.553 MHz, CDCl3, ppm): 178.8 (NCN); 130.8,
128.9, 128.6, 128.4 (CArom), 50.2 (CHIsopropyl), 24.7 (CH3 Isopropyl),
22.8 (CH3 AgOAc).
109Ag NMR (23.278 MHz, CDCl3, ppm): 533.
Elemental Analysis calculated for C23H27N2AgO2: Calculated: C,
58.60; H, 5.77; N, 5.94; Found: C, 58.83; H, 5.85; N, 5.87.
IR (KBr, cm1): 3055 (w,v), 2973 (w,v), 1715 (w), 1368 (m),
1329 (m), 1113 (w), 760 (m), 699 (s), 616 (m), 523 (w).
Melting point: 178 C.
2.5.4. Synthesis of 1-isopropyl-3-methyl-4,5-diphenylimidazol-2-
ylidene silver(I) acetate (6)
Silver(I) complex 6, was prepared as a light brown solid. (0.110
g, 24% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.37–7.31 (6H, CHArom, m),
7.18–7.15 (4H, CHArom, m), 4.34 (1H, CHIsopropyl, Pent, 7 Hz), 3.78
(3H, CH3 Methyl, s), 2.12 (3H, CH3 AgOAc), 1.65 (6H, CH3 Isopropyl, d,
7 Hz).
13C NMR (100.553 MHz, CDCl3, ppm): 179.1 (NCN), 130.8, 130.2,
129.2, 128.9, 128.8, 128.6, 128.0 (CArom), 49.9 (CH2 Benzyl), 24.8 (CH3
Isopropyl), 22.9 (CH3 AgOAc).
109Ag NMR (23.278 MHz, CDCl3, ppm): 499.
Elemental Analysis calculated for C21H23N2AgO2: Calculated: C,
56.88; H, 5.23; N, 6.32; Found: C, 56.55; H, 5.19; N, 6.40.IR (KBr, cm1): 3655 (w), 3056 (w,v), 2975 (w,v), 1568 (m),
1378 (m,v), 1328 (m,v), 765 (m), 699 (s), 665 (m), 526 (w).
Melting point: 195–200 C.
2.5.5. Synthesis of 1-methyl-3-benzyl-4,5-diphenylimidazol-2-ylidene
silver(I) acetate (7)
Silver(I) complex 7, was prepared as a light brown solid. (0.130
g, 26% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.34–7.30 (4H, CHArom, m),
7.27–7.21 (5H, CHArom, m), 7.18–7.15 (2H, CHArom, m), 7.02–6.97
(2H, CHArom, m), 5.27 (2H, CH2 Benzyl, s), 3.78 (3H, CH3 Methyl, s),
2.09 (3H, CH3 AgOAc, s).
13C NMR (100.553 MHz, CDCl3, ppm): 178.8 (NCN), 136.2, 132.7,
132.1, 130.77, 130.3, 129.2, 129.1, 128.7, 128.6, 127.9, 127.9, 127.7,
127.5 (CArom), 53.4 (CBenzyl), 37.8 (CMethyl), 22.5 (CAgOac).
109Ag NMR (23.278 MHz, CDCl3, ppm): 476.
Elemental Analysis calculated for C27H27N2AgO2: Calculated: C,
61.77; H, 4.71; N, 5.70; Found: C, 60.82; H, 4.71; N, 5.50.
IR (KBr, cm1): 3054 (w,v), 2920 (w,v) 1704 (w), 1573 (m,v),
1379 (m), 1257 (m), 735 (s,v), 696 (s), 617 (m), 514 (w).
Melting point: 118–120 C.
2.5.6. Synthesis of 1-isopropyl-3-benzyl-4,5-diphenylimidazol-2-
ylidene silver(I) acetate (8)
Silver(I) complex 8, was prepared as a light brown solid. (0.060
g, 12% yield).
1H NMR (399.899 MHz, CDCl3, ppm): 7.35–7.29 (4H, CHArom, m),
7.24–7.20 (5H, CHArom, m), 7.17–7.15 (2H, CHArom, m), 7.00–6.94
(4H, CHArom, ddd, 12, 7.5, 2.5 Hz), 5.33 (2H, CHBenzyl, s), 4.39 (1H,
CHIsopropyl, hept, 7 Hz), 2.10 (3H, CH3 AgOAc, s), 1.70 (6H, CH3 Isopropyl,
d, 7 Hz).
13C NMR (100.553 MHz, CDCl3, ppm): 179.0 (NCN), 136.3, 130.8,
130.7, 129.2, 128.9, 128.7, 128.6, 128.5, 128.0, 127.9, 127.9, 127.3
(CArom), 54.5 (CBenzyl), 50.1 (CHisopropyl), 24.8 (CH3 isopropyl), 22.8
(CAgOAc).
109Ag NMR (23.278 MHz, CDCl3, ppm): 506.
Elemental Analysis calculated for C27H27N2AgO2: Calculated: C,
62.43; H, 5.23; N, 5.39; Found: C, 62.05; H, 5.08; N, 5.16.
IR (KBr, cm1): 3056 (w,v), 2972 (w,v), 1716 (w), 1570 (m),
1375 (m), 1329 (m), 700 (s), 666 (s), 617 (m), 576 (m).
Melting point: 176–178 C.
2.6. Antibacterial studies
Preliminary in vitro biological studies were carried out to assess
the antibacterial effect of the newly synthesised symmetrical and
non-symmetrical derivatives of SBC3 against two pathogenic bac-
terial strains. Methicillin-Resistant Staphylococcus aureus (ATCC
43300) was chosen as the Gram-positive bacterial test strain and
Escherichia coli (ATCC 25922) chosen as the Gram-negative bacte-
rial test strain.
To test the biological activity of the novel complexes, 3–8, the
Kirby–Bauer disk diffusion method was used [19]. Both bacterial
strains were cultured in 2 ml LB medium from single colonies at
37 C for 24 h whilst shaking. All antibacterial work was carried
out under sterile conditions.
For both bacterial strains, 50 mL of culture was spread over agar-
LB medium in a petri plate. To each plate, 5.5 mmWhatman paper
disks were evenly placed into four marked quadrants. Stock solu-
tions of 1 mg/ml of each silver complex in DMSO were made, with
two volumes of 5 mL and 10 mL tested for each complex against
both bacterial strains.
DMSO, without the addition of a silver complex, was used with
each round of testing as a control in 5 mL and 10 mL volumes. Plates
were covered and incubated at 37 C for 24 h. The area of clearance
is defined as the distance between the beginning of bacterial
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was measured in millimetres (mm).Table 1
Recorded 109Ag NMR resonance shifts
for novel silver(I) complexes.
Complex 109Ag shift (d ppm)
SBC3 488
3 476
4 480
5 533
6 499
7 476
8 5063. Results and discussion
3.1. Synthesis
With the objective of understanding the influence of changing
non-polar substituents at the 1 and 3 position of the SBC3 silver
(I) complex (Fig. 1), a series of NHC imidazolium salts were synthe-
sized and their corresponding silver(I) complexes were produced.
With the incorporation of the silver acetate moiety as the primary
antimicrobial agent, the derivatisation of the NHC imidazole back-
bone was a logical step to try and increase the biological efficacy.
By incorporating alkyl chains at the 1 and 3 positions of the imi-
dazole ring, lower molecular weight silver(I) complexes were syn-
thesized to increase the ‘drug-like’ character of this class. Six novel
lower weight derivatives of the SBC3 molecule have been synthe-
sized (Scheme 1) and tested for antibiotic activity. All silver com-
plexes were characterised by spectroscopic and analytical
methods, with elemental analysis of C, H, N, and crystal structure
data obtained for certainty of structure and purity.
Using 4,5-diphenyl imidazole as the starting material, the
mono-alkylated imidazoles of 1-methyl and 1-isopropyl-4,5-
diphenyl imidazole were synthesized by adjusted literature meth-
ods [20]; both were confirmed by NMR spectroscopy and elemen-
tal analysis.
The symmetrical imidazolium salt precursors of complexes 3, 4
& 5 were synthesized under high pressure and high temperature
conditions with 4,5-diphenyl imidazole and potassium carbonate
added to a Teflon container with a small amount of acetonitrile.
The corresponding ligand (iodomethane; bromoethane; 2-bromo-
propane) was then injected before the container was sealed in a
stainless steel casing and heated at 120 C for 3 days. All reactions
were filtered, concentrated and precipitated from solution using
diethyl ether in yields of 81%, 89% and 85% for the precursors of sil-
ver(I) complexes 3, 4 and 5, respectively. All imidazolium salts
were confirmed through NMR spectroscopy and elemental analysis
and compared to literature values [20,29,30].
The non-symmetrical imidazolium salt precursors of complexes
6, 7 & 8 were synthesized from the previously mentioned mono-
alkylated imidazoles. The precursor imidazolium salt to complex
6 was synthesized using the same high pressure and high temper-
ature conditions and the same workup procedure as for the salt
precursors of 3, 4 & 5; the imidazolium salt was confirmed by
NMR spectroscopy, elemental analysis and compared to literature
values [20]. The precursor imidazolium salt for silver(I) complexScheme 1. Synthesis of symmetrical and non-symmetrical imidazolium s7 was synthesized by refluxing 1-methyl-4,5-diphenyl imidazole
and benzyl bromide for 24 h, and worked up as the other precursor
salts to obtain the desired product in 90% yield. The precursor imi-
dazolium salt for silver(I) complex 8was synthesized by stirring 1-
isopropyl-4,5-diphenyl imidazole and benzyl bromide for 3 days at
room temperature. The reaction was worked up as the other pre-
cursor salts to obtain the desired imidazolium salt in 54% yield.
The corresponding silver(I) acetate complexes, 3–8, were all
synthesized by stirring the respective precursor imidazolium salt
with two equivalents of silver acetate in dry dichloromethane,
under nitrogen, in a lightproof flask for 3 days. All products were
filtered, washed with dry dichloromethane, concentrated and pre-
cipitated with diethyl ether. All complexes were placed in a 4 C
freezer for 12 h to allow greater precipitation to achieve yields
between 12% and 54%. Several of the imidazolium salts proved less
reactive than others with silver acetate under these conditions, and
the corresponding silver(I) complexes (4, 6, 7, 8) required post-pre-
cipitation purification using a pencil column, made from a cotton
wool bud and one inch of Davisil 40–63 micron silica inside a Pas-
teur pipette.
The precursor imidazolium salt to the SBC3 molecule was syn-
thesized in an improved yield of 98% using a modified literature
method [15]. 4,5-Diphenyl imidazole and 2.2 equivalents of benzyl
bromide were reacted under reflux at 85 C for 24 h in 50 ml ace-
tonitrile and worked up as previous precursor salts. The SBC3
molecule was synthesized by literature method in a yield of 59%
by reacting silver acetate with the precursor imidazolium salt in
dry dichloromethane for 3 days at room temperature, in darkness.
The complex was worked up as the other silver(I) complexes.
3.2. NMR spectroscopy
All of the imidazolium salt intermediates and silver(I) com-
plexes were fully characterised by 1H, 13C NMR spectroscopy, along
with further analysis by 109Ag NMR spectroscopy for the silver(I)
complexes. All previously published imidazoles and imidazoliumalt precursors, and their corresponding NHC–silver(I) complexes 3–8.
Table 2
Crystal data and structural refinement information for complexes 3–8.
Identification code 3 4 5 6 7 8
Empirical formula C19H23N2O4Ag C21H23N2O2Ag C24H29N2O2Cl2Ag C43H48N4O4Cl2Ag2 C25.64H24.28N2O2Cl1.28Ag C27H27N2O2Ag
Molecular formula C19H19N2O2Ag  2 (H2O) C23H27N2O2Ag  CH2Cl2 (C21H23N2O2Ag)2  CH2Cl2 C25H23N2O2Ag  0.64
(CH2Cl2)
Formula weight 451.26 443.28 556.26 971.49 545.78 519.37
Crystal system triclinic triclinic orthorhombic triclinic orthorhombic triclinic
Space group P–1 (#2) P–1 (#2) P212121 (#19) P–1 (#2) Pna21 (#33) P–1 (#2)
Unit cell dimensions/Å()
a = 8.5705(2) b = 9.1007(2) a = 14.60488(6) b = 16.07477
(7)
a = 8.89667(7) b = 9.20695
(7)
a = 8.9450(2) b = 9.5119
(2)
a = 15.1362(2) b = 11.37991
(9)
a = 10.09486(8) b = 10.9479(1)
c = 13.2387(3) Å a = 99.037
(2)
c = 18.86008(9) a = 70.2548
(4)
c = 29.3893(3) a = 90 c = 13.5607(2) a = 71.653
(2)
c = 28.5638(2) a = 90 c = 12.1433(1) a = 96.2856(7)
b = 105.107(2) c = 93.185
(2)
b = 70.2548(4) c = 75.3434
(3)
b = 90 c = 90 b = 83.779(2) c = 73.152
(2)
b = 90 c = 90 b = 111.1459(7) c = 105.4602
(8)
V (Å3) 979.47(4) 3915.50(3) 2407.31(4) 1047.96(4) 4920.07(8) 1174.395(19)
Z 2 8 4 1 8 2
Dcalc(Mg/m3) 1.530 1.504 1.535 1.539 1.474 1.469
Absorption coefficient (mm1) 8.471 1.046 8.941 9.035 8.045 7.084
F (000) 460 1808 1136 494 2215.4 532
Crystal size (mm3) 0.241  0.174  0.039 0.325  0.240  0.169 0.2152  0.1344  0.1165 0.202  0.154  0.093 0.197  0.138  0.125 0.194  0.122  0.086
Theta range for data collection () 3.514–76.848 2.85–33.02 3.01–76.72 3.434–76.849 4.182–77.060 4.010–76.989
Index ranges 10  h  10,
11  k  11,
16  l  16
21  h  21,
24  k  24,
28  l  28
7  h  11,
11  k  11,
36  l  33
11  h  11,
11  k  11,
17  l  17
16  h  18
14  k  14
35  l  35
12  h  12,
11  k  13,
15  l  15
Reflections collected 21048 241717 17276 20542 115490 46914
Independent reflections 4081 [Rint = 0.0283] 28036 [Rint = 0.0397] 5001 [Rint = 0.0354] 4351 [Rint = 0.0665] 10325 [Rint = 0.0454] 4920 [Rint = 0.0288]
Completeness to h = 67.684 100.00% 99.40% 99.20% 99.80% 99.80% 100.00%
Absorption correction gaussian gaussian analytical gaussian gaussian gaussian
Maximum and minimum
transmission
0.736 and 0.227 0.877 and 0.774 0.503 and 0.306 0.643 and 0.375 0.496 and 0.291 0.666 and 0.422
Data/restraints/parameters 4081/0/245 28036/0/949 5001/0/285 4351/0/294 10325/1/601 4920/0/330
Goodness-of-fit (GOF) on F2 1.041 1.088 1.019 1.117 1.059 1.084
Final R indices [I > 2r(I)] R1 = 0.0206, wR2 = 0.0527 R1 = 0.0306, wR2 = 0.0714 R1 = 0.0217, wR2 = 0.0540 R1 = 0.0481, wR2 = 0.1194 R1 = 0.0482, wR2 = 0.1413 R1 = 0.0350, wR2 = 0.0814
R indices (all data) R1 = 0.0224, wR2 = 0.0537 R1 = 0.0420, wR2 = 0.0789 R1 = 0.0228, wR2 = 0.0546 R1 = 0.0568, wR2 = 0.1470 R1 = 0.0496, wR2 = 0.1434 R1 = 0.0398, wR2 = 0.0857
Largest difference peak and hole (e
Å3)
0.442 and 0.507 3.186 and 1.328 0.650 and 0.502 1.924 and 1.869 1.404 and 0.855 0.905 and 1.589
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Fig. 2. Crystal structures of symmetrical and non-symmetrical complexes 3–7; X-ray diffraction of all complexes thermal ellipsoids are drawn on the 50% probability level;
disorder neglected for structure of complex 6.
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[HYPERLINK "SPS:refid::bib15_bib20_bib27_bib28"15,20,27,28].
In the case of the imidazolium salts, a singlet peak can be clearly
seen on the 1H spectra in the range of d = 10.38–11.39 ppm. This
corresponds to literature values for imidazolium salts with halogen
anions (Br, I) [15,19,24–28], as the proton attached to the
carbene carbon of the imidazole ring becomes deshielded due to
the positive nature of the imidazolium and presence of the
anionic halide counter ion [10].
For all silver(I) complexes, there is the distinctive loss of the
carbene proton signal in the range d = 10.38–11.39 ppm, and there
is the presence of the new silver acetate CH3 singlet peak in the
range d = 2.09–2.13 ppm.
For complexes 3–8, the 13C resonances for the carbene carbon
fall within the region of d = 177.0–179.2 ppm, as seen in previous
publication [15]. Along with the shifted carbene signals, the silver
acetate CH3 group is the other characteristic peak that is present inthe 13C NMR spectrum after complexation, falling in the range of d
= 22.5–22.9 ppm.
109Ag NMR was conducted on all silver complexes and the cor-
responding broad resonance peaks (d ppm) were found, as shown
in Table 1. The NMR resonances of the silver complexes were
determined on a w/v concentration basis, with 100 mg of silver(I)
complex to 0.6 ml deuterated chloroform as the solvent.
The different substituent patterns at the 1 and 3 positions of the
imidazole ring will directly affect the electronic properties of the
carbene carbon. These electronic effects result in differentiations
in NMR shifts, as is the case for the carbene hydrogen in the imida-
zolium salt precursors and now in the shifts of the silver moiety in
the complexes.
These values were found within a similar region to a previously
reported imidazole NHC–silver(I) chloride complex that resolves a
109Ag NMR signal at d = 597 ppm, in deuterated acetonitrile [31],
and a previously reported dinuclear silver OTf complex resolving
Fig. 3. Crystal structure of complex 8; thermal ellipsoids are drawn on the 50%
probability level, disorder neglected.
C. O’Beirne et al. / Polyhedron 149 (2018) 95–103 101a Ag NMR signal at d = 541 ppm, in deuterated chloroform [32109].
No literature values could be found for NHC–silver(I) acetate com-
plexes for direct comparison.
Each 109Ag signal was resolved as a broad signal, despite the rel-
ative low sensitivity experiment. The signal for the SBC3 molecule
resolved at d = 488 ppm; with two benzyl groups on the 1 and 3
positions, this was used as the standard comparison against the
six novel complexes.
The signals of the three symmetrical silver(I) complexes stea-
dily shift further upfield with the increase in atoms on the carbon
chain, with a larger up-field shift when isopropyl groups are incor-
porated in complex 5. For the non-symmetrical compounds we
again see the influence of the isopropyl group compared to the
methyl substituent. Comparing the shift of complex 3 (d = 476
ppm) to that of complex 7 (d = 476 ppm), there does not seem to
be a large influence from the benzyl substituent.
The largest downfield shifts seen in this series are associated
with the complexes containing isopropyl groups. The jump of 12
ppm in the silver chemical shift for complex 8 compared to SBC3
seems to result from a single substitution of the benzyl group by
an isopropyl one. This jump is even more pronounced with a 55
ppm shift for the complex 5 after the outright replacement of ben-
zyl groups with isopropyl substituents. This isopropyl effect seems
to indicate a large downfield field shift even with a single replace-
ment of the methyl, ethyl or benzyl substituents with an isopropyl
group.Table 3
Selected bond lengths and angles for silver(I) complexes 3–8.
3 4a 5
Bond length (Å)
C(1)AN(1) 1.352(2) 1.352(2) 1.3
C(1)AN(2) 1.349(3) 1.353(2) 1.3
N(1)AC(2) 1.393(2) 1.3928(19) 1.3
C(2)AC(3) 1.362(3) 1.365(2) 1.3
C(3)AN(2) 1.393(2) 1.395(2) 1.3
AgAC(1) 2.0705(19) 2.0667(16) 2.0
AgAO(1) 2.0986(14) 2.1336(13) 2.1
Bond angle ()
C(1)AAgAO(1) 172.74(6) 173.36(6) 176
N(1)AC(1)AN(2) 104.99(16) 104.84(13) 104
a First molecule in the asymmetric unit; all others have very similar values.
b Affected by disorder, see text.3.3. IR spectroscopy
In the IR spectra of all silver complexes there are consistent
absorptions in the region of 1560–1580 cm1 corresponding to
the C@O stretching vibration of the g1-bonded acetate group,
which is consistent with previously reported complexes
[15,19,24–28]. All complexes also show low-intensity absorptions
just above and under the 3000 cm1 region, which are correspond-
ing to aromatic and aliphatic CAH stretching vibrations, and strong
absorptions in the 695–750 cm1 region that correspond to the
phenyl CAH bending vibrations.
3.4. Crystal structure data
Crystal data of 3–8 were collected using an Rigaku Oxford
Diffraction (former Agilent Technologies, former Oxford Diffrac-
tion) SuperNova A diffractometer fitted with an Atlas detector. 4
was measured with Mo Ka (0.71073 Å), all others with Cu Ka
(1.54184 Å). A complete dataset was collected, assuming that the
Friedel pairs are not equivalent. An analytical absorption correc-
tion based on the shape of the crystal was performed [33]. The
structures were solved by direct methods using [34] and refined
by full matrix least-squares on F2 for all data using [34SHELXSSHELXL].
Refinement data can be seen in Table 2.
The hydrogen atoms of the water molecules in 3were located in
the difference Fourier map. In subsequent refinements the water
molecules were restrained to have the ideal shape using DFIX. After
convergence the water molecules were refined as rigid groups. All
other hydrogen atoms were added at calculated positions and
refined using a riding model. Their isotropic temperature factors
were fixed to 1.2 times (1.5 times for methyl groups and water
hydrogens) the equivalent isotropic displacement parameters of
the parent atom. Anisotropic thermal displacement parameters
were used for all non-hydrogen atoms.
Appropriate crystals of complexes 3–8 were obtained for X-ray
crystallography by the slow diffusion of pentane into a small vol-
ume of a saturated solution of dichloromethane at 2 C, Figs. 2
and 3.
Selected bond lengths and angles are listed in Table 3. Both the
shapes of the imidazole rings and the AgAC bond length agree very
well with previously reported values [15,19,24–28].
In all complexes reported here the AgAO bond length is even
shorter than the one in the SBC3 molecule [15], with the possible
exception of the minor disorder part in 8. All CAAgAO bond angles
are close to 180, again with the possible exception of 8. There the
acetate group is disordered in such a way that both monodentate
and bidentate binding to the silver atom seem to be present.
However, the displacement ellipsoid of the silver atom indicates
that it may also be disordered. An attempt to refine this led to6 7a 8
60(3) 1.378(7) 1.346(9) 1.349(3)
55(3) 1.361(6) 1.333(8) 1.344(4)
98(3) 1.391(6) 1.406(8) 1.400(4)
53(3) 1.365(7) 1.358(9) 1.359(5)
98(3) 1.388(6) 1.393(8) 1.397(3)
80(2) 2.065(5) 2.080(7) 2.073(3)
119(18) 2.138(4) 2.109(6) 2.133(4)b
.50(8) 167.23(16) 170.6(3) 165.7(3)b
.64(19) 103.6(4) 105.6(6) 105.4(2)
Table 4
Kirby–Bauer areas of clearance for complexes 3–8, SBC3 and Tetracycline (TC) against selected bacterial strains.
Silver(I) complex MRSA E. coli
Volumes [ml] 5 10 5 10
Area of clearance
SBC3 9 mm 10 mm 2 mm 2 mm
3 3 mm 3 mm 1 mm 2 mm
4 2 mm 3 mm 1 mm 2 mm
5 2 mm 2 mm 1 mm 1 mm
6 1 mm 2 mm 1 mm 2 mm
7 3 mm 4 mm 1 mm 1 mm
8 1 mm 3 mm 2 mm 1 mm
TC 14 mm 15 mm 11 mm 13 mm
102 C. O’Beirne et al. / Polyhedron 149 (2018) 95–103unreasonably high correlations due to the close proximity of the
disorder positions, but the result suggests that in both disorder
parts the acetate coordinates to the silver in the same way, with
the Ag-O1 distance about 2.1 Å, the AgAO2 distance about 2.8 Å
and the CAAgAO angle about 175. In conclusion, the binding
mode of the acetate to the silver in 8 cannot be determined with
certainty. In all other complexes reported here there is no hint of
a bidentate coordination of the acetate to the silver. No argen-
tophilic interactions were observed in any of the complexes
reported here.3.5. Antibacterial testing
In vitro antibacterial studies were carried out for the six novel
silver(I) complexes using the qualitative Kirby–Bauer disk diffusion
method of testing. The corresponding antibacterial results are out-
lined in Table 4. Antibacterial activity was determined against the
drug-resistant, gram-positive bacteria Methicillin-resistant Staphy-
lococcus aureus (MRSA) and the gram-negative bacteria Escherichia
coli.
Along with the new complexes, the SBC3 molecule and Tetracy-
cline were used as standards for antibacterial activity. SBC3 is the
premier antibiotic that has been found for this class of NHC–silver
(I) compounds and Tetracycline is the base compound for an entire
family of clinical level antibacterial medicines. Each represents a
standard required for firstly providing good antibacterial effect,
and then the requirement of further activity for a clinic level
antibiotic.
From Table 4 we can see that the most effective complex with
the largest area of clearances is that with the incorporated benzyl
group, complex 7, with 4 mm of clearance against MRSA at a vol-
ume of 10 ml. It is followed by the other benzyl containing complex,
8, and two of the symmetrical complexes 3 and 4 with 3 mm of
clearance at a 10 ml volume.
Despite the lower molecular weight of the newly synthesized
complexes, they did not achieve the antibacterial efficacy of SBC3
or Tetracycline. These results would suggest that the incorporation
of lower molecular weight substituents in place of the lipophilic
benzyl groups highlight the importance of chemical structures that
incorporate biologically important effects over lower molecular
weight. Despite these results, this work has concluded that the
1,3-dibenzy-4,5-diphenyl imidazole is an optimised NHC-back-
bone for coinage metals to utilise in future antibacterial work.4. Conclusion
The synthesis and subsequent characterisation of these three
symmetrical and three non-symmetrical novel N-heterocyclic car-
bene silver(I) complexes have been synthesized and full charac-
terised, showing several interesting chemical behaviourshighlighted by their crystallographic and 109Ag NMR spectroscopic
data.
The 109Ag NMR data of these molecules shows the effect of the
substitution pattern on the chemical shift of the silver atom with
the incorporation of isopropyl groups inducing large downfield
chemical shifts. The crystallographic data from the six complexes
shows similar linearity in their bonding from the NHC carbene car-
bon to the silver atom, with no argentophilic interactions found.
However, with complex 8 we see the definite interaction of both
the acetate oxygen and carbonyl oxygen with the silver atom in
g2-coordination, with the bond lengths found as 2.133(4) Å for
the bond with the acetate oxygen (OA1A) and 2.634(8) Å for the
bond with the carbonyl oxygen (OA2A).
Biological data shows that the most effective of these com-
pounds against MRSA was complex 7, with clearances of 4 mm
clearance in the Kirby–Bauer disk diffusion test, though unfortu-
nately this activity was not as pronounced as SBC3 complex or
Tetracycline. These derivatisations have shown that the 1,3-
dibenzy-4,5-diphenyl imidazole is the most optimised imidazole
NHC backbone for this complex category, and should be incorpo-
rated for future NHC–silver antibiotic compounds.
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Appendix A. Supplementary data
CCDC 1818518, 1818516, 1818515, 1818519, 1818517 and
1818520 contains the supplementary crystallographic data for 3–
8. These data can be obtained free of charge via http://www.
ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crys-
tallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK;
fax: (+44) 1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk.
References
[1] https://www.cdc.gov/drugresistance/threat-report-2013/index.html, (2013)
last accessed: 15/2/18.
[2] http://www.who.int/drugresistance/documents/surveillancereport/en/, (2014)
ISBN: 978 92 4 156474 8, last accessed: 15/2/18.
[3] J. Davies, D. Davies, Microbiol. Mol. Biol. Rev. 74 (2010) 417.
[4] Y. Liu et al., Lancet Infect. Dis. 16 (2015) 161.
[5] S.B. Levy, B. Marshall, Nat. Med. 10 (2004) S122.
[6] J.R. Morones-Ramirez, J.A. Winkler, C.S. Spina, J.J. Collins, Sci. Transl. Med. 5
(2013) 190ra81.
[7] S. Silver, FEMS Microbiol. Rev. 27 (2003) 341.
[8] K. Mijnendonckx, N. Leys, J. Mahillon, S. Silver, R. Van Houdt, Biometals 26
(2013) 609.
[9] A.J. Arduengo III, R.L. Harlow, M.J. Kline, Am. Chem. Soc. 113 (1991) 361.
[10] A. Kascatan-Nebioglu, A. Melaiye, K. Hindi, S. Durmus, M.J. Panzner, L.A. Hogue,
R.J. Mallett, C.E. Hovis, M. Coughenour, S.D. Crosby, A. Milsted, D.L. Ely, C.A.
Tessier, C.L. Cannon, W.J. Youngs, J. Med. Chem. 49 (2006) 6811.
C. O’Beirne et al. / Polyhedron 149 (2018) 95–103 103[11] S.A. Patil, S.A. Patil, R. Patil, R.S. Keri, S. Budagumpi, G.T. Balakrishna, M. Tacke,
Future Med. Chem. 7 (2015) 1305.
[12] M.N. Hopkinson, C. Richter, M. Schedler, F. Glorius, Nature 510 (2014) 485.
[13] A. Kascatan-Nebioglu, M.J. Panzner, C.A. Tessier, C.L. Cannon, W.J. Youngs,
Coord. Chem. Rev. 251 (2007) 884.
[14] M.V. Baker, P.J. Barnard, S.J. Berners-Price, S.K. Brayshaw, J.L. Hickey, B.W.
Skelton, A.H. White, Dalton Trans. (2006) 3708.
[15] S. Patil, A. Deally, B. Gleeson, H. Müller-Bunz, F. Paradisi, M. Tacke, Metallomics
3 (2011) 74.
[16] M.A. Sharkey, J.P. O’Gara, S.V. Gordon, F. Hackenberg, C. Healy, F. Paradisi, S.
Patil, B. Schaible, M. Tacke, Antibiotics 1 (2012) 25.
[17] N. Browne, F. Hackenberg, W. Streciwilk, M. Tacke, K. Kavanagh, Biometals 27
(2014) 745.
[18] C.A. Lipinski, F. Lombardo, D.W. Dominy, P.J. Feeney, Adv. Drug Deliv. Rev. 46
(2001) 3.
[19] W. Streciwilk, J. Cassidy, F. Hackenberg, H. Müller-Bunz, F. Paradisi, M. Tacke, J.
Organomet. Chem. 749 (2014) 88.
[20] A.R. Chianese, A. Kovacevic, B.M. Zeglis, J.W. Faller, R.H. Crabtree,
Organometallics 23 (2004) 2461.
[21] W.Walther, O. Dada, C. O’Beirne, I. Ott, G. Sánchez-Sanz, C. Schmidt, C. Werner,
X. Zhu, M. Tacke, LDDD 14 (2017) 125.[22] J.C. Garrison, W.J. Youngs, Chem. Rev. 105 (2005) 3978.
[23] K. Zangger, I.M. Armitage, Metal-Based Drugs 6 (1999) 239.
[24] S. Patil, J. Claffey, A. Deally, M. Hogan, B. Gleeson, L.Mi. Menendez Mendez, H.
Müller-Bunz, F. Paradisi, M. Tacke, Eur. J. Inorg. Chem. 7 (2010) 1020.
[25] S. Patil, A. Deally, B. Gleeson, F. Hackenberg, H. Müller-Bunz, F. Paradisi, M.
Tacke, Z. Anorg. Allg. Chem. 637 (2011) 386.
[26] F. Hackenberg, G. Lally, H. Müller-Bunz, F. Paradisi, D. Quaglia, W. Streciwilk,
M. Tacke, Inorg. Chim. Acta 395 (2013) 135.
[27] S. Patil, K. Dietrich, A. Deally, B. Gleeson, H. Müller-Bunz, F. Paradisi, M. Tacke,
Helv. Chim. Acta 93 (2010) 2297.
[28] F. Hackenberg, G. Lally, H. Müller-Bunz, F. Paradisi, D. Quaglia, W. Streciwilk,
M. Tacke, J. Organomet. Chem. 717 (2012) 123.
[29] H.M. Lima, C.J. Lovely, Org. Lett. 13 (2011) 5736.
[30] W. Liu, K. Bensdorf, M. Proetto, U. Abram, A. Hagenbach, R. Gust, J. Med. Chem.
54 (2011) 8605.
[31] B.K. Tate, C.M. Wyss, J. Basca, K. Kluge, L. Gelbaum, J.P. Sadighi, Chem. Sci. 4
(2013) 3068.
[32] J.P. Canal, T. Ramnial, D.A. Dickie, J.A.C. Clyburne, Chem. Commun. (2006)
1809.
[33] R.C. Clarke, J.S. Reid, Acta Cryst. A51 (1995) 615.
[34] G.M. Sheldrick, Acta Cryst. A64 (2008) 112.
